EUVIMEDPoznaj EUVIMED
Open access · CC BY-NC-ND 4.0

Metabolic shift underlies tumor progression and immune evasion in S‐nitrosoglutathione reductase‐deficient cancer

Rafael Mena-Osuna, Ana Mantrana, Silvia Guil-Luna iD, María Teresa Sánchez-Montero, Carmen Navarrete-Sirvent, Teresa Morales-Ruiz, Aurora Rivas-Crespo, Marta Toledano-Fonseca, María Victoria García-Ortíz, Gema García-Jurado, María Auxiliadora Gómez-España, Rafael González-Fernández and 5 more

The Journal of Pathology · 2023

DOI: 10.1002/path.6080 ↗

At a glance

Journal article in The Journal of Pathology, 2023. Written by Rafael Mena-Osuna and 16 co-authors. Institution: Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain. Major MEDLINE topics: Oxidoreductases, Neoplasms. Cited 7 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Ministerio de Ciencia e Innovación, Universidad de Córdoba.

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

S‐nitrosoglutathione reductase (GSNOR) is a denitrosylase enzyme that has been suggested to play a tumor suppressor role, although the mechanisms responsible are still largely unclear. In this study, we show that GSNOR deficiency in tumors is associated with poor prognostic histopathological features and poor survival in patients with colorectal cancer (CRC). GSNOR‐low tumors were characterized by an immunosuppressive microenvironment with exclusion of cytotoxic CD8 + T cells. Notably, GSNOR‐low tumors exhibited an immune evasive proteomic signature along with an altered energy metabolism characterized by impaired oxidative phosphorylation (OXPHOS) and energetic dependence on glycolytic activity. CRISPR‐Cas9‐mediated generation of GSNOR gene knockout (KO) CRC cells confirmed in vitro and in vivo that GSNOR‐deficiency conferred higher tumorigenic and tumor‐initiating capacities. Moreover, GSNOR‐KO cells possessed enhanced immune evasive properties and resistance to immunotherapy, as revealed following xenografting them into humanized mouse models. Importantly, GSNOR‐KO cells were characterized by a metabolic shift from OXPHOS to glycolysis to produce energy, as indicated by increased lactate secretion, higher sensitivity to 2‐deoxyglucose (2DG), and a fragmented mitochondrial network. Real‐time metabolic analysis revealed that GSNOR‐KO cells operated close to their maximal glycolytic rate, as a compensation for lower OXPHOS levels, explaining their higher sensitivity to 2DG. Remarkably, this higher susceptibility to glycolysis inhibition with 2DG was validated in patient‐derived xenografts and organoids from clinical GSNOR‐low tumors. In conclusion, our data support the idea that metabolic reprogramming induced by GSNOR deficiency is an important mechanism for tumor progression and immune evasion in CRC and that the metabolic vulnerabilities associated with the deficiency of this denitrosylase can be exploited therapeutically. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

OxidoreductasesNeoplasmsMiceAnimalsHumansCD8-Positive T-LymphocytesImmune EvasionProteomicsTumor MicroenvironmentAldehyde Oxidoreductases

Author keywords

GSNORcolorectal cancerglycolysisimmune evasionimmunotherapymetabolismmitochondrianitric oxideoxidative phosphorylation

Substances

Oxidoreductasesformaldehyde dehydrogenase, glutathione-independentAldehyde Oxidoreductases

Authors and institutions

  • Maimonides Biomedical Research Institute of Córdoba (IMIBIC), Córdoba, Spain.
  • Cancer Network Biomedical Research Centre (CIBERONC), Madrid, Spain.
  • Department of Medicine, Faculty of Medicine, University of Córdoba, Córdoba, Spain.
  • Department of Genetics, University of Córdoba, Córdoba, Spain.
  • Medical Oncology Department, Reina Sofía University Hospital, Córdoba, Spain.
  • Immunology Department, Reina Sofia University Hospital, Córdoba, Spain.

ORCID profiles: Silvia Guil-Luna, Antonio Rodríguez-Ariza

Funding

  • Ministerio de Ciencia e Innovación
  • Universidad de Córdoba

Cite

APA

Mena-Osuna, R., Mantrana, A., Guil-Luna, S., Sánchez-Montero, M. T., Navarrete-Sirvent, C., Morales-Ruiz, T., Rivas-Crespo, A., Toledano-Fonseca, M., García-Ortíz, M. V., García-Jurado, G., Gómez-España, M. A., González-Fernández, R., Villar, C., Medina-Fernández, F. J., Villalba, J. M., Aranda, E., & Rodríguez-Ariza, A. (2023). Metabolic shift underlies tumor progression and immune evasion in S‐nitrosoglutathione reductase‐deficient cancer. The Journal of Pathology. https://doi.org/10.1002/path.6080

Vancouver

Mena-Osuna R, Mantrana A, Guil-Luna S, Sánchez-Montero MT, Navarrete-Sirvent C, Morales-Ruiz T, et al. Metabolic shift underlies tumor progression and immune evasion in S‐nitrosoglutathione reductase‐deficient cancer. The Journal of Pathology. 2023. doi:10.1002/path.6080

BibTeX
@article{MenaOsuna2023,
  author = {Mena-Osuna, Rafael and Mantrana, Ana and Guil-Luna, Silvia and Sánchez-Montero, María Teresa and Navarrete-Sirvent, Carmen and Morales-Ruiz, Teresa and Rivas-Crespo, Aurora and Toledano-Fonseca, Marta and García-Ortíz, María Victoria and García-Jurado, Gema and Gómez-España, María Auxiliadora and González-Fernández, Rafael and Villar, Carlos and Medina-Fernández, Francisco Javier and Villalba, José Manuel and Aranda, Enrique and Rodríguez-Ariza, Antonio},
  title = {Metabolic shift underlies tumor progression and immune evasion in S‐nitrosoglutathione reductase‐deficient cancer},
  journal = {The Journal of Pathology},
  year = {2023},
  doi = {10.1002/path.6080}
}
Start for free →